ARCHIVES

Consolidation Unlikely to Save Money

This article is from The Cancer Letter archive.

Vol. 36 No. 46 | December 17, 2010

Download PDF Visit The Full Archive

Related Articles

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

Cancer Training Programs Fairing Fairley Well

December 1, 1989

Flow Lab Lands Top Virology Contract – $1.9 Mil.

February 21, 1975

Shared Decisionmaking Called For In PSA Screening For Ages 55-69

May 31, 2013

In Brief: Hedlund To Head Prostate Cancer Coalition; USCF Forms Human Genetics Program

July 25, 1997

With Fighter Planes Overhead, ODAC Kept Deliberating.

September 21, 2001